Japan could become one of the first countries in the world to end the HIV epidemic, says the president of Gilead Sciences Japan, Kennet Brysting. The idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of medicines that can prevent transmission of HIV. Drugs are not the cure, but control over the spread of virus to the point where the disease is no longer a major public health threat.

What Is The Role Of Preventative HIV Medicines?

Gilead's have two key drugs, Truvada and lenacapavir. These two are playing a crucial role in prevention. Truvada is taken as a daily pill, while lenacapavir requires two injections per year. It can make the virus undetectable in infected individuals and prevent transmission to those who are not infected yet. In trials, lenacapavir showed 100% efficacy in preventing HIV infections. This is why it is describe as "almost a vaccine".

In 2024, Japan also approved Truvada for HIV prevention, but the country has yet to approve lenacapavir for the same. Until now, people in Japan had been importing generic versions of Truvada or purchasing it from clinics that source it from overseas.

HIV In Japan

Up until now, Japan reported around 25,000 HIV infections, whereas 669 new cases were reported in 2023. For seven consecutive years, the number of new infections remained under 1,000. The downward trend thus shows that the virus has been controlled, however, getting to zero new infections remains the ultimate goal.

Brysting too acknowledged that simply having effective drug is not enough. What is important is to have a proper implementation, access and healthcare support to make sure that these treatments are widely available and effective.

What Are The Challenges In Implementation?

The biggest challenges is testing rates. There is a need to increase testing rates. At this very moment, around 86% people infective with Japan have been tested, but the goal is to increase it up to 95%, with an ideal goal of 100%. Without widespread testing, many infected people may not even know that they are infected and it could transmit the virus.

Another measure issue is the cost of preventative medication. While Japan's health insurance covers treatments for diseases, it does not cover preventative drugs. Those who purchase Truvada for prevention, pay around $470 per month. Some clinics in Tokyo offer generic alternatives too, which is cheaper, but they are not ideal.

Better Healthcare Support

Brysting expressed concern that individuals importing medications might not be consulting doctors regularly, which is essential for monitoring HIV status and overall health. Truvada users need to be tested for HIV initially and every three months, along with screenings for other infections and kidney function checks. Without proper medical supervision, there is a risk of misuse and inadequate protection.

Gilead is in discussions with Japanese authorities to improve access and insurance coverage for Truvada, and progress is being made. Japan has shown efficiency in approving critical medicines, as seen during the COVID-19 pandemic when Gilead’s remdesivir was approved in just three days.

What Is The Way Ahead?

Gilead at this moment is not only focused on HIV and hepatitis C, but also expanding into oncology with innovative treatments like CAR-T cell therapy, which strengthens a patient's immune system to fight cancer.

However, Japan’s strict approval processes can slow down drug availability. Phase 3 clinical trials often need to be conducted within the country, and Japan tends to approve medicines much later than other regions. For instance, Truvada was approved for prevention in Japan 12 years after the U.S. and nearly 20 years after its approval for treatment. inancial factors also play a role. The Japanese government adjusts drug prices annually, often reducing them, which can make long-term investment challenging for pharmaceutical companies.

US researchers have identified the first known infection caused by Bourbon virus in a man from New York's Long Island, raising concerns that the rare tick-borne virus may have gone undetected for years.

The case, published in the American Journal of Tropical Medicine and Hygiene, suggests that the virus could be circulating more widely in the Long Island region than previously believed.

Because Bourbon virus causes symptoms similar to more common tick-borne illnesses, including Lyme disease, experts believe some infections may have been misdiagnosed.

What Is the Case?

In 2021, 67-year-old Michael Larkin was bitten by two lone star ticks while working outdoors. However, it took about 5 years to get a proper diagnosis.

Because his symptoms resembled those of more common tick-borne illnesses, including Lyme disease, doctors initially treated him with antibiotics. However, since antibiotics do not work against viral infections, his condition worsened and he developed fever, rash, night sweats and debilitating headaches.

The lack of a commercially available diagnostic test further complicated his diagnosis, making it difficult for physicians to identify the virus during the acute stage of illness.

Larkin's illness was confirmed to have been caused by Bourbon virus recently, after he got enrolled in a year-long antibody study, with blood samples collected every three months.

"Now we know the virus can be lethal. On Long Island, at least, we have a lot of lone star ticks," Dr. Luis Marcos, who treated Larkin, told CBS News. "And honestly this may be the very, very tip of the iceberg."

What Is Bourbon Virus?

Bourbon virus is a rare tick-borne virus believed to spread through the bite of infected lone star ticks (Amblyomma americanum).

According to the US Centers for Disease Control and Prevention (CDC), cases have previously been reported in parts of the Midwest, East Coast and Southern United States.

The virus was first identified in 2014 and was named after Bourbon County, Kansas, where it was initially discovered. There is currently no vaccine to prevent Bourbon virus infection and no specific antiviral treatment.

Symptoms of Bourbon Virus

People infected with Bourbon virus have reported symptoms including:

• Fever
• Fatigue
• Rash
• Headache
• Muscle and body aches
• Nausea and vomiting

• Low white blood cell counts
• Low platelet counts

How Does It Spread?

Bourbon virus is believed to spread through the bite of infected lone star ticks. These aggressive ticks are identified by the single white spot—or "lone star"—on the backs of adult females. They are commonly found in wooded areas, brush and tall grass.

Lone star ticks are also known to transmit several other diseases, including:

• Ehrlichiosis
• Tularemia
• Alpha-gal syndrome (red meat allergy)

Could More Cases Be Going Undetected?

The researchers noted that the Bourbon virus is likely more prevalent than we think in New York and other cases are likely not being diagnosed.

Marcos added that the findings highlight the urgent need for improved surveillance, expanded testing and better guidance for healthcare providers.

"Without identifying the cause of an infection, the chances of developing accurate diagnostic tests or effective treatments are minimal," Marcos said. "That is why it is so important to first understand the true impact of the virus in high-risk areas."

How to Prevent The Deadly Infection?

Health experts recommend taking the following precautions:

• Protect yourself from tick bites by avoiding wooded, brushy and grassy areas whenever possible.
• Stay in the center of hiking trails.
• Wear long sleeves and long pants outdoors.
• Treat clothing and gear with 0.5% permethrin.
• Use EPA-registered insect repellents containing ingredients such as DEET.
• Check your body, clothing and pets for ticks after spending time outdoors and remove attached ticks promptly.

Scientists have discovered an Achilles' heel that helps some of the most aggressive cancers escape treatment. The discovery that could pave the way for new targeted therapies against specific drug-resistant tumours.

Researchers at Nanyang Technological University (NTU) Singapore, identified a protein called TEX264 that enables cancer cells to escape the therapeutic effects of a widely used class of targeted cancer drugs known as PARP inhibitors. The study is published in Nature Cell Biology.

What Does This Mean For Drug-Resistant Cancers?

The findings could have positive implications for patients with triple-negative breast cancer, as well as ovarian, prostate, and pancreatic cancers that are treated with PARP inhibitors. These cancers eventually become resistant to the drugs.

"Our findings have identified a new biological process involving TEX264 as a key mechanism of drug resistance in an aggressive form of cancer," said Professor Kristijan Ramadan, who led the research. "We coined this new biological mechanism 'autophagy of DNA lesions', or simply 'nucleophagy'. This makes TEX264 a potential target for future cancer therapies."

Also read: Don't Fear The Biopsy, Fear The Delay

How Do Some Cancers Escape Treatment?

PARP inhibitors work by blocking PARP1, a protein that repairs damaged DNA inside cancer cells. Without this repair system, tumour cells accumulate DNA damage and die. However, many cancers eventually become resistant to this treatment.

The researchers discovered that TEX264 helps remove trapped PARP1 proteins from damaged DNA through a newly identified clean-up process called nucleophagy, allowing cancer cells to continue repairing themselves and escape the treatment. This is the cellular recycling system that makes cancer resistant to treatments.

When scientists blocked TEX264 in experiments, PARP1 remained stuck on DNA, DNA damage accumulated, and the cancer cells became far more vulnerable to therapy.

Also read: US FDA Approves New Blood Test To Screen For Colorectal Cancer

What Are PARP Inhibitors?

They are approved for several cancers, including ovarian, breast, prostate, and pancreatic cancer.

While many patients initially respond well, resistance develops in an estimated 40% to 70% of breast and ovarian cancer cases.

Also read: Scientists Find Rare Contagious Skin Cancer In Fish From US, Canada: Should Humans Worry?

Importance Of This Study

Instead of targeting the DNA repair machinery directly, the new study targets an entirely different weak spot, the cellular cycle that cancer cells exploit to discard damaged repair proteins.

Researchers believe drugs that inhibit TEX264 or block nucleophagy could potentially restore the effectiveness of existing PARP inhibitors, offering a new targeted treatment strategy for patients whose cancers no longer respond to therapy.

The researchers caution that the findings are currently based on laboratory studies, and more research, including clinical trials, will be needed before therapies targeting TEX264 can reach patients.

The promising results adds to growing efforts worldwide to overcome one of oncology's biggest challenges: preventing cancers from evolving resistance to life-saving treatments.

The World Health Organization (WHO) has updated its treatment guidelines for visceral leishmaniasis (VL), commonly known as kala-azar, and post-kala-azar dermal leishmaniasis (PKDL).

Through this update, WHO is recommending shorter, safer and more patient-friendly treatments that could improve outcomes for thousands of patients across eastern Africa and South-East Asia.

The revised guidance marks the first major update in nearly two decades for these forms of leishmaniasis.

It introduces new treatment options, including the use of oral miltefosine in combination therapies, reducing the need for long courses of painful daily injections.

What Is PKDL?

Post-kala-azar dermal leishmaniasis (PKDL) is a skin condition that appears months or years after a patient recovers from visceral leishmaniasis.

Visceral leishmaniasis, also known as kala-azar or black fever, is a life-threatening parasitic disease caused by Leishmania. It is spread by infected female sandflies. It attacks internal organs like the spleen and liver and is almost always fatal if left untreated.

In post-kala-azar, while patients usually feel well, they develop patches, papules or nodules on the skin that harbour the parasite. This allows sandflies to transmit the infection to others.

Early diagnosis and effective treatment of PKDL are therefore considered essential for interrupting transmission and elimination of kala-azar.

Also read: Uganda Declared Ebola-Free As Congo Outbreak Grows To 3,262 Cases, 1,437 Deaths

About The New Treatment Guidelines

WHO now recommends a 14-day regimen combining oral miltefosine with once-daily paromomycin injections for patients with primary visceral leishmaniasis in eastern Africa.

The new approach replaces older sodium stibogluconate-based regimens that required 17 days of treatment, 34 injections, which were often associated with toxicity.

The guidelines also introduce shorter treatment options for PKDL. For patients in eastern Africa and South-East Asia, WHO recommends new combination treatments that substantially shorten duration. It also allows part of the therapy to be completed at home.

Dr Daniel Ngamije Madandi, WHO Director of Malaria and Neglected Tropical Diseases, "For too long, patients suffering from leishmaniasis have endured treatments nearly as punishing as the disease itself. By recommending safer, shorter and more patient-friendly regimens, we are not just improving care; we are accelerating our fight to eliminate this devastating disease and offering renewed hope to communities across Africa and Asia."

Also read: Ebola Scare In The UK After Humanitarian Worker Monitored In London Hospital; Here's what Happened

Milestone In PKDL Treatment

The updated recommendations also revise the safety guidance for miltefosine in line with advice from the WHO Advisory Committee on the Safety of Medicinal Products and introduce allometric dosing to help optimise treatment across different body weights.

Kala-azar is one of the world's deadliest parasitic diseases after malaria. According to WHO, eastern Africa accounted for nearly 79% of global visceral leishmaniasis cases in 2024, with around half of patients being children under the age of 15.

Transmitted through the bite of infected female sandflies, it causes prolonged fever, weight loss, anaemia and enlargement of the spleen and liver. If left untreated, the disease is fatal in up to 95% of cases.